Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE) (RE-COVER II)

8. mai 2014 oppdatert av: Boehringer Ingelheim

A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication

The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic VTE.

The primary objective is to investigate the efficacy of dabigatran compared to warfarin during the 6 month treatment period. The investigation of other selected efficacy aspects and safety are regarded as secondary objective of this trial.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

2589

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Australia
    • New South Wales
      • Concord, New South Wales, Australia
        • 1160.46.61007 Boehringer Ingelheim Investigational Site
    • Victoria
      • Box Hill, Victoria, Australia
        • 1160.46.61003 Boehringer Ingelheim Investigational Site
      • Clayton, Victoria, Australia
        • 1160.46.61001 Boehringer Ingelheim Investigational Site
      • Windsor, Victoria, Australia
        • 1160.46.61006 Boehringer Ingelheim Investigational Site
    • Western Australia
      • Perth, Western Australia, Australia
        • 1160.46.61005 Boehringer Ingelheim Investigational Site
  • Brasil
      • Brasília, Brasil
        • 1160.46.55010 Boehringer Ingelheim Investigational Site
      • Campinas, Brasil
        • 1160.46.55007 Boehringer Ingelheim Investigational Site
      • Curitiba, Brasil
        • 1160.46.55014 Boehringer Ingelheim Investigational Site
      • Curitiba, Brasil
        • 1160.46.55017 Boehringer Ingelheim Investigational Site
      • Porto Alegre, Brasil
        • 1160.46.55019 Boehringer Ingelheim Investigational Site
      • Recife, Brasil
        • 1160.46.55021 Boehringer Ingelheim Investigational Site
      • Rio de Janeiro - RJ, Brasil
        • 1160.46.55016 Boehringer Ingelheim Investigational Site
      • São Bernardo do Campo, Brasil
        • 1160.46.55018 Boehringer Ingelheim Investigational Site
      • São Paulo, Brasil
        • 1160.46.55020 Boehringer Ingelheim Investigational Site
  • Bulgaria
      • Sofia, Bulgaria
        • 1160.46.35901 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.46.35903 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.46.35906 Boehringer Ingelheim Investigational Site
      • Varna, Bulgaria
        • 1160.46.35905 Boehringer Ingelheim Investigational Site
  • Canada
      • Quebec, Canada
        • 1160.46.02020 Boehringer Ingelheim Investigational Site
    • Alberta
      • Edmonton, Alberta, Canada
        • 1160.46.02006 Boehringer Ingelheim Investigational Site
      • Edmonton, Alberta, Canada
        • 1160.46.02013 Boehringer Ingelheim Investigational Site
    • British Columbia
      • Victoria, British Columbia, Canada
        • 1160.46.02021 Boehringer Ingelheim Investigational Site
    • New Brunswick
      • Saint John, New Brunswick, Canada
        • 1160.46.02004 Boehringer Ingelheim Investigational Site
    • Nova Scotia
      • Halifax, Nova Scotia, Canada
        • 1160.46.02001 Boehringer Ingelheim Investigational Site
    • Ontario
      • Hamilton, Ontario, Canada
        • 1160.46.02002 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Canada
        • 1160.46.02005 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Canada
        • 1160.46.02010 Boehringer Ingelheim Investigational Site
      • Ottawa, Ontario, Canada
        • 1160.46.02015 Boehringer Ingelheim Investigational Site
      • Toronto, Ontario, Canada
        • 1160.46.02019 Boehringer Ingelheim Investigational Site
    • Quebec
      • Montreal, Quebec, Canada
        • 1160.46.02008 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, Canada
        • 1160.46.02009 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, Canada
        • 1160.46.02014 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, Canada
        • 1160.46.02017 Boehringer Ingelheim Investigational Site
  • Danmark
      • Aarhus C, Danmark
        • 1160.46.45001 Boehringer Ingelheim Investigational Site
      • Esbjerg, Danmark
        • 1160.46.45008 Boehringer Ingelheim Investigational Site
      • Holbæk, Danmark
        • 1160.46.45009 Boehringer Ingelheim Investigational Site
      • København NV, Danmark
        • 1160.46.45004 Boehringer Ingelheim Investigational Site
  • Den russiske føderasjonen
      • Chelyabinsk, Den russiske føderasjonen
        • 1160.46.07021 Boehringer Ingelheim Investigational Site
      • Ekaterinburg, Den russiske føderasjonen
        • 1160.46.07007 Boehringer Ingelheim Investigational Site
      • Krasnodar, Den russiske føderasjonen
        • 1160.46.07016 Boehringer Ingelheim Investigational Site
      • Kursk, Den russiske føderasjonen
        • 1160.46.07004 Boehringer Ingelheim Investigational Site
      • Rostov-na-Donu, Den russiske føderasjonen
        • 1160.46.07009 Boehringer Ingelheim Investigational Site
      • Rostov-na-Donu, Den russiske føderasjonen
        • 1160.46.07024 Boehringer Ingelheim Investigational Site
      • Ufa, Den russiske føderasjonen
        • 1160.46.07014 Boehringer Ingelheim Investigational Site
      • Yaroslavl, Den russiske føderasjonen
        • 1160.46.07005 Boehringer Ingelheim Investigational Site
      • Yaroslavl, Den russiske føderasjonen
        • 1160.46.07006 Boehringer Ingelheim Investigational Site
  • Filippinene
      • Manila, Filippinene
        • 1160.46.63001 Boehringer Ingelheim Investigational Site
      • Muntinlupa, Filippinene
        • 1160.46.63005 Boehringer Ingelheim Investigational Site
      • Quezon City, Filippinene
        • 1160.46.63003 Boehringer Ingelheim Investigational Site
      • Quezon City, Filippinene
        • 1160.46.63004 Boehringer Ingelheim Investigational Site
  • Forente stater
    • Arkansas
      • Little Rock, Arkansas, Forente stater
        • 1160.46.01073 Boehringer Ingelheim Investigational Site
    • Florida
      • Clearwater, Florida, Forente stater
        • 1160.46.01044 Boehringer Ingelheim Investigational Site
    • Illinois
      • Normal, Illinois, Forente stater
        • 1160.46.01068 Boehringer Ingelheim Investigational Site
    • Louisiana
      • Shreveport, Louisiana, Forente stater
        • 1160.46.01071 Boehringer Ingelheim Investigational Site
    • New York
      • Stony Brook, New York, Forente stater
        • 1160.46.01060 Boehringer Ingelheim Investigational Site
    • Ohio
      • Columbus, Ohio, Forente stater
        • 1160.46.01061 Boehringer Ingelheim Investigational Site
    • Oregon
      • Bend, Oregon, Forente stater
        • 1160.46.01059 Boehringer Ingelheim Investigational Site
      • Corvallis, Oregon, Forente stater
        • 1160.46.01063 Boehringer Ingelheim Investigational Site
    • South Carolina
      • Summerville, South Carolina, Forente stater
        • 1160.46.01055 Boehringer Ingelheim Investigational Site
    • Washington
      • Bellevue, Washington, Forente stater
        • 1160.46.01062 Boehringer Ingelheim Investigational Site
  • Frankrike
      • Brest Cedex, Frankrike
        • 1160.46.3301A Boehringer Ingelheim Investigational Site
      • Brest Cedex, Frankrike
        • 1160.46.3301B Boehringer Ingelheim Investigational Site
      • La Roche-Sur-Yon cedex 09, Frankrike
        • 1160.46.3315A Boehringer Ingelheim Investigational Site
      • La Roche-Sur-Yon cedex 09, Frankrike
        • 1160.46.3315B Boehringer Ingelheim Investigational Site
      • Nantes, Frankrike
        • 1160.46.3313A Boehringer Ingelheim Investigational Site
      • Pessac, Frankrike
        • 1160.46.3316A Boehringer Ingelheim Investigational Site
      • Pessac, Frankrike
        • 1160.46.3316B Boehringer Ingelheim Investigational Site
      • St Etienne Cedex 2, Frankrike
        • 1160.46.3303C Boehringer Ingelheim Investigational Site
      • St Etienne Cedex 2, Frankrike
        • 1160.46.3303D Boehringer Ingelheim Investigational Site
      • St Etienne Cedex 2, Frankrike
        • 1160.46.3303E Boehringer Ingelheim Investigational Site
      • St Etienne Cedex 2, Frankrike
        • 1160.46.3303F Boehringer Ingelheim Investigational Site
      • St Etienne Cedex 2, Frankrike
        • 1160.46.3303G Boehringer Ingelheim Investigational Site
      • St Etienne Cedex 2, Frankrike
        • 1160.46.3303H Boehringer Ingelheim Investigational Site
      • St Priest En Jarez Cedex, Frankrike
        • 1160.46.3303A Boehringer Ingelheim Investigational Site
      • St Priest En Jarez Cedex, Frankrike
        • 1160.46.3303B Boehringer Ingelheim Investigational Site
  • India
      • Bangalore, India
        • 1160.46.91006 Boehringer Ingelheim Investigational Site
      • Bangalore, India
        • 1160.46.91010 Boehringer Ingelheim Investigational Site
      • Chennai, India
        • 1160.46.91002 Boehringer Ingelheim Investigational Site
      • Chennai, India
        • 1160.46.91007 Boehringer Ingelheim Investigational Site
      • Kolkata, India
        • 1160.46.91012 Boehringer Ingelheim Investigational Site
      • Ludhiana, India
        • 1160.46.91009 Boehringer Ingelheim Investigational Site
      • Nagpur, India
        • 1160.46.91008 Boehringer Ingelheim Investigational Site
      • New Delhi, India
        • 1160.46.91005 Boehringer Ingelheim Investigational Site
      • New Delhi, India
        • 1160.46.91014 Boehringer Ingelheim Investigational Site
      • Pune, India
        • 1160.46.91001 Boehringer Ingelheim Investigational Site
      • Pune, India
        • 1160.46.91004 Boehringer Ingelheim Investigational Site
      • Tamil Nadu, India
        • 1160.46.91011 Boehringer Ingelheim Investigational Site
      • Vadodara, India
        • 1160.46.91013 Boehringer Ingelheim Investigational Site
      • Vadodra, India
        • 1160.46.91003 Boehringer Ingelheim Investigational Site
  • Israel
      • Afula, Israel
        • 1160.46.97202 Boehringer Ingelheim Investigational Site
      • Ashkelon, Israel
        • 1160.46.97207 Boehringer Ingelheim Investigational Site
      • DN Lower Galillee, Israel
        • 1160.46.97212 Boehringer Ingelheim Investigational Site
      • Haifa, Israel
        • 1160.46.97211 Boehringer Ingelheim Investigational Site
      • Holon, Israel
        • 1160.46.97203 Boehringer Ingelheim Investigational Site
      • KfarSaba, Israel
        • 1160.46.97205 Boehringer Ingelheim Investigational Site
      • Nazareth, Israel
        • 1160.46.97209 Boehringer Ingelheim Investigational Site
      • Petah Tiqwa, Israel
        • 1160.46.97206 Boehringer Ingelheim Investigational Site
      • Tel Aviv, Israel
        • 1160.46.97210 Boehringer Ingelheim Investigational Site
      • Tel Hashomer, Ramat Gan, Israel
        • 1160.46.97204 Boehringer Ingelheim Investigational Site
      • Zerifin, Israel
        • 1160.46.97201 Boehringer Ingelheim Investigational Site
  • Italia
      • Catania, Italia
        • 1160.46.39011 Boehringer Ingelheim Investigational Site
      • Firenze, Italia
        • 1160.46.39015 Boehringer Ingelheim Investigational Site
      • Palermo, Italia
        • 1160.46.39012 Boehringer Ingelheim Investigational Site
      • Reggio Emilia, Italia
        • 1160.46.39007 Boehringer Ingelheim Investigational Site
      • Verona, Italia
        • 1160.46.39013 Boehringer Ingelheim Investigational Site
      • Vittorio Veneto (TV), Italia
        • 1160.46.39005 Boehringer Ingelheim Investigational Site
  • Kina
      • Beijing, Kina
        • 1160.46.86001 Boehringer Ingelheim Investigational Site
      • Beijing, Kina
        • 1160.46.86002 Boehringer Ingelheim Investigational Site
      • Beijing, Kina
        • 1160.46.86019 Boehringer Ingelheim Investigational Site
      • Guangzhou, Kina
        • 1160.46.86014 Boehringer Ingelheim Investigational Site
      • Guangzhou, Kina
        • 1160.46.86015 Boehringer Ingelheim Investigational Site
      • Hangzhou, Kina
        • 1160.46.86016 Boehringer Ingelheim Investigational Site
      • Shanghai, Kina
        • 1160.46.86003 Boehringer Ingelheim Investigational Site
      • Shanghai, Kina
        • 1160.46.86004 Boehringer Ingelheim Investigational Site
      • Shanghai, Kina
        • 1160.46.86005 Boehringer Ingelheim Investigational Site
      • Shanghai, Kina
        • 1160.46.86011 Boehringer Ingelheim Investigational Site
      • Shenyang, Kina
        • 1160.46.86007 Boehringer Ingelheim Investigational Site
      • Shijiazhuang, Kina
        • 1160.46.86017 Boehringer Ingelheim Investigational Site
      • Shijiazhuang, Kina
        • 1160.46.86018 Boehringer Ingelheim Investigational Site
      • Taiyuan, Kina
        • 1160.46.86021 Boehringer Ingelheim Investigational Site
      • Tianjin, Kina
        • 1160.46.86006 Boehringer Ingelheim Investigational Site
      • Yinchuan, Kina
        • 1160.46.86020 Boehringer Ingelheim Investigational Site
  • Korea, Republikken
      • Busan, Korea, Republikken
        • 1160.46.82007 Boehringer Ingelheim Investigational Site
      • Goyang-si, Korea, Republikken
        • 1160.46.82003 Boehringer Ingelheim Investigational Site
      • Gyeonggi-do, Korea, Republikken
        • 1160.46.82008 Boehringer Ingelheim Investigational Site
      • Gyeonggi-do, Korea, Republikken
        • 1160.46.82010 Boehringer Ingelheim Investigational Site
      • Kyunggi-do, Korea, Republikken
        • 1160.46.82002 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republikken
        • 1160.46.82004 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republikken
        • 1160.46.82005 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republikken
        • 1160.46.82006 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republikken
        • 1160.46.82009 Boehringer Ingelheim Investigational Site
  • Malaysia
      • Kelantan Kota Bahru, Malaysia
        • 1160.46.60001 Boehringer Ingelheim Investigational Site
      • Melaka, Malaysia
        • 1160.46.60003 Boehringer Ingelheim Investigational Site
      • Pahang, Malaysia
        • 1160.46.60004 Boehringer Ingelheim Investigational Site
      • Selangor, Malaysia
        • 1160.46.60002 Boehringer Ingelheim Investigational Site
  • Nederland
      • Alkmaar, Nederland
        • 1160.46.31017 Boehringer Ingelheim Investigational Site
      • Amersfoort, Nederland
        • 1160.46.31001 Boehringer Ingelheim Investigational Site
      • Den Bosch, Nederland
        • 1160.46.31010 Boehringer Ingelheim Investigational Site
      • Eindhoven, Nederland
        • 1160.46.31013 Boehringer Ingelheim Investigational Site
      • Heerlen, Nederland
        • 1160.46.31014 Boehringer Ingelheim Investigational Site
      • Nieuwegein, Nederland
        • 1160.46.31002 Boehringer Ingelheim Investigational Site
      • Rotterdam, Nederland
        • 1160.46.31004 Boehringer Ingelheim Investigational Site
      • Zwolle, Nederland
        • 1160.46.31015 Boehringer Ingelheim Investigational Site
  • New Zealand
      • Christchurch, New Zealand
        • 1160.46.64004 Boehringer Ingelheim Investigational Site
      • Grafton Auckland, New Zealand
        • 1160.46.64003 Boehringer Ingelheim Investigational Site
      • Otahuhu Auckland, New Zealand
        • 1160.46.64002 Boehringer Ingelheim Investigational Site
      • Takapuna Auckland, New Zealand
        • 1160.46.64001 Boehringer Ingelheim Investigational Site
  • Norge
      • Oslo, Norge
        • 1160.46.47001 Boehringer Ingelheim Investigational Site
      • Trondheim, Norge
        • 1160.46.47005 Boehringer Ingelheim Investigational Site
  • Polen
      • Kielce, Polen
        • 1160.46.48004 Boehringer Ingelheim Investigational Site
      • Krakow, Polen
        • 1160.46.48001 Boehringer Ingelheim Investigational Site
      • Krakow, Polen
        • 1160.46.48005 Boehringer Ingelheim Investigational Site
      • Poznan, Polen
        • 1160.46.48003 Boehringer Ingelheim Investigational Site
      • Warsaw, Polen
        • 1160.46.48006 Boehringer Ingelheim Investigational Site
  • Singapore
      • Singapore, Singapore
        • 1160.46.65001 Boehringer Ingelheim Investigational Site
      • Singapore, Singapore
        • 1160.46.65002 Boehringer Ingelheim Investigational Site
      • Singapore, Singapore
        • 1160.46.65003 Boehringer Ingelheim Investigational Site
  • Slovakia
      • Banska Bystrica, Slovakia
        • 1160.46.42107 Boehringer Ingelheim Investigational Site
      • Lucenec, Slovakia
        • 1160.46.42106 Boehringer Ingelheim Investigational Site
      • Nitra, Slovakia
        • 1160.46.42102 Boehringer Ingelheim Investigational Site
      • Nove Zamky, Slovakia
        • 1160.46.42103 Boehringer Ingelheim Investigational Site
  • Spania
      • Barcelona, Spania
        • 1160.46.34002 Boehringer Ingelheim Investigational Site
      • Cartagena. Murcia, Spania
        • 1160.46.34007 Boehringer Ingelheim Investigational Site
      • Madrid, Spania
        • 1160.46.34009 Boehringer Ingelheim Investigational Site
      • Palma de Mallorca, Spania
        • 1160.46.34015 Boehringer Ingelheim Investigational Site
      • Sabadell - barcelona, Spania
        • 1160.46.34014 Boehringer Ingelheim Investigational Site
      • Valencia, Spania
        • 1160.46.34011 Boehringer Ingelheim Investigational Site
  • Storbritannia
      • Headington, Oxford, Storbritannia
        • 1160.46.44005 Boehringer Ingelheim Investigational Site
      • London, Storbritannia
        • 1160.46.44011 Boehringer Ingelheim Investigational Site
      • Newcastle upon Tyne, Storbritannia
        • 1160.46.44006 Boehringer Ingelheim Investigational Site
      • Plymouth, Storbritannia
        • 1160.46.44013 Boehringer Ingelheim Investigational Site
      • Sheffield, Storbritannia
        • 1160.46.44012 Boehringer Ingelheim Investigational Site
  • Sverige
      • Göteborg, Sverige
        • 1160.46.46002 Boehringer Ingelheim Investigational Site
      • Kristianstad, Sverige
        • 1160.46.46010 Boehringer Ingelheim Investigational Site
      • Stockholm, Sverige
        • 1160.46.46001 Boehringer Ingelheim Investigational Site
      • Stockholm, Sverige
        • 1160.46.46008 Boehringer Ingelheim Investigational Site
      • Uppsala, Sverige
        • 1160.46.46003 Boehringer Ingelheim Investigational Site
  • Sør-Afrika
      • Bryanston, Sør-Afrika
        • 1160.46.27001 Boehringer Ingelheim Investigational Site
      • Cape Town, Sør-Afrika
        • 1160.46.27013 Boehringer Ingelheim Investigational Site
      • Centurion, Sør-Afrika
        • 1160.46.27007 Boehringer Ingelheim Investigational Site
      • Kempton Park, Sør-Afrika
        • 1160.46.27014 Boehringer Ingelheim Investigational Site
      • Krugersdorp, Sør-Afrika
        • 1160.46.27015 Boehringer Ingelheim Investigational Site
      • Morningside, Sør-Afrika
        • 1160.46.27002 Boehringer Ingelheim Investigational Site
      • Plumstead, Sør-Afrika
        • 1160.46.27012 Boehringer Ingelheim Investigational Site
      • Sunninghill, Sør-Afrika
        • 1160.46.27006 Boehringer Ingelheim Investigational Site
  • Taiwan
      • ChangHua, Taiwan
        • 1160.46.88607 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.46.88604 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.46.88606 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.46.88608 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.46.88609 Boehringer Ingelheim Investigational Site
  • Thailand
      • Bangkok, Thailand
        • 1160.46.66007 Boehringer Ingelheim Investigational Site
      • Bangkok, Thailand
        • 1160.46.66010 Boehringer Ingelheim Investigational Site
      • Khon Kaen, Thailand
        • 1160.46.66001 Boehringer Ingelheim Investigational Site
      • Muang Nakhonratchasima, Thailand
        • 1160.46.66004 Boehringer Ingelheim Investigational Site
      • Nakhonratchasima, Thailand
        • 1160.46.66005 Boehringer Ingelheim Investigational Site
      • Nokorn Nayok, Thailand
        • 1160.46.66006 Boehringer Ingelheim Investigational Site
      • Phayathai, Thailand
        • 1160.46.66008 Boehringer Ingelheim Investigational Site
  • Tsjekkisk Republikk
      • Brno, Tsjekkisk Republikk
        • 1160.46.42001 Boehringer Ingelheim Investigational Site
      • Hradec Kralove, Tsjekkisk Republikk
        • 1160.46.42002 Boehringer Ingelheim Investigational Site
      • Liberec, Tsjekkisk Republikk
        • 1160.46.42012 Boehringer Ingelheim Investigational Site
      • Litomerice, Tsjekkisk Republikk
        • 1160.46.42018 Boehringer Ingelheim Investigational Site
      • Novy Jicin, Tsjekkisk Republikk
        • 1160.46.42015 Boehringer Ingelheim Investigational Site
      • Ostrava-Vitkovice, Tsjekkisk Republikk
        • 1160.46.42005 Boehringer Ingelheim Investigational Site
      • Prague 4, Tsjekkisk Republikk
        • 1160.46.42017 Boehringer Ingelheim Investigational Site
      • Tabor, Tsjekkisk Republikk
        • 1160.46.42014 Boehringer Ingelheim Investigational Site
      • Teplice, Tsjekkisk Republikk
        • 1160.46.42016 Boehringer Ingelheim Investigational Site
      • Usti nad Labem, Tsjekkisk Republikk
        • 1160.46.42010 Boehringer Ingelheim Investigational Site
      • Zlin, Tsjekkisk Republikk
        • 1160.46.42007 Boehringer Ingelheim Investigational Site
  • Tyrkia
      • Ankara, Tyrkia
        • 1160.46.90003 Boehringer Ingelheim Investigational Site
      • Ankara, Tyrkia
        • 1160.46.90004 Boehringer Ingelheim Investigational Site
      • Istanbul, Tyrkia
        • 1160.46.90001 Boehringer Ingelheim Investigational Site
      • Istanbul, Tyrkia
        • 1160.46.90002 Boehringer Ingelheim Investigational Site
      • Istanbul, Tyrkia
        • 1160.46.90007 Boehringer Ingelheim Investigational Site
      • Istanbul, Tyrkia
        • 1160.46.90008 Boehringer Ingelheim Investigational Site
      • Istanbul, Tyrkia
        • 1160.46.90009 Boehringer Ingelheim Investigational Site
      • Istanbul, Tyrkia
        • 1160.46.90010 Boehringer Ingelheim Investigational Site
  • Ukraina
      • Vinnitsa, Ukraina
        • 1160.46.38005 Boehringer Ingelheim Investigational Site
  • Ungarn
      • Debrecen, Ungarn
        • 1160.46.36002 Boehringer Ingelheim Investigational Site
      • Szekesfehervar, Ungarn
        • 1160.46.36010 Boehringer Ingelheim Investigational Site
      • Szombathely, Ungarn
        • 1160.46.36011 Boehringer Ingelheim Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion criteria:

  • Acute symptomatic uni- or bilateral Deep Vein Thrombosis (DVT) of the leg involving proximal veins, and/or Pulmonary Embolism (PE)
  • Male or female, being 18 years of age or older
  • Written informed consent for study participation

Exclusion criteria:

  • Persistent symptoms of VTE
  • PE requiring urgent intervention
  • Use of vena cava filter
  • Contraindications to anticoagulant therapy
  • Allergy to study medications
  • Elevated Aspartate-aminotransferase (AST) or Alanine-aminotransferase (ALT) > 3x Upper Limit of Normal (ULN) or known liver disease expected to have an impact on survival
  • Severe renal impairment
  • Patients considered unsuitable for inclusion

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Dabigatran etexilate (150mg bid)
Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily
Legemiddel: Dabigatran etexilate
150mg bid
Aktiv komparator: Warfarin (INR 2.0-3.0)
Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0
Legemiddel: Warfarin
PRN (to maintain a target INR of 2.0-3.0)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall deltakere med tilbakevendende symptomatisk venøs tromboembolisme (VTE) og dødsfall relatert til VTE
Tidsramme: For statistisk analyse 1: fra randomisering til slutten av postbehandlingsperioden (ptp), planlagt til dag 224. For statistisk analyse 2: fra randomisering til 6 måneder (opp til dag 180)
Alle mistenkte tilbakevendende VTE og alle dødsfall og blødningshendelser ble evaluert av en uavhengig sentral bedømmelseskomité, og alle analyser er basert på hendelsene som ble sentralt bekreftet av denne komiteen.
For statistisk analyse 1: fra randomisering til slutten av postbehandlingsperioden (ptp), planlagt til dag 224. For statistisk analyse 2: fra randomisering til 6 måneder (opp til dag 180)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants With Recurrent Symptomatic VTE and All Deaths
Tidsramme: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
VTE or any death which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Number of Participants With Recurrent Symptomatic DVT
Tidsramme: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Symptomatic DVT which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Number of Participants With Recurrent Symptomatic Non-fatal PE
Tidsramme: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Symptomatic non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Number of Participants Who Died Due to VTE
Tidsramme: From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)
VTE - related deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee. Hazard ratios and 95% CI were not calculated because of insufficient number of events.
From randomisation to 6 months (up to day 180) and to end of ptp (planned to be up to day 224)
Number of Participants Who Died (Any Cause)
Tidsramme: For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Any deaths which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Number of Participants With Recurrent Symptomatic Fatal and Non-fatal PE
Tidsramme: For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Symptomatic fatal and non-fatal PE which occured from randomisation to end of ptp. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee.
For statistical analysis 1: from randomisation to 6 months (up to day 180). For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.
Number of Participants With MBE, MBE and/or CRBE, and Any Bleeding Events
Tidsramme: From first intake of study drug to last intake of study drug + 6 days washout

Major bleeding events (MBE) are defined as

  • Fatal bleeding
  • Symptomatic bleeding in a critical area or organ
  • Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells

Clinically-relevant bleeding events (CRBE) are defined as

  • spontaneous skin hematoma >=25 cm²
  • wound hematoma >=100 cm²
  • spontaneous nose bleed >5 min
  • macroscopic hematuria spontaneous or >24 hours if associated with an intervention
  • spontaneous rectal bleeding
  • gingival bleeding >5 min
  • leading to hospitalisation and / or requiring surgical treatment
  • leading to a transfusion of <2 units of whole blood or red cells
  • any other bleeding event considered clinically relevant by the investigator

Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.
From first intake of study drug to last intake of study drug + 6 days washout
Number of Participants With Acute Coronary Syndrome (ACS)
Tidsramme: From first intake of study drug to last contact date
Any ACS occurring during the conduct of the study (centrally adjudicated as definite). Patients having a centrally adjudicated definite ACS during intake of study drug and after stopping study drug, according to treatment group. ACS assessments pre-specified in the protocol without adjudication. Prior to database lock, the steering committee asked to have ACS events adjudicated by an independent committee. After database lock, the committee was provided with source documentation that was blinded to the patient's treatment assignment. ACS results presented are based on adjudication findings.
From first intake of study drug to last contact date
Laboratory Analyses
Tidsramme: From first intake of study drug to last intake of study drug + 6 days washout
Frequency of patients with possible clinically significant abnormalities.
From first intake of study drug to last intake of study drug + 6 days washout

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Boehringer Ingelheim

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. april 2008

Primær fullføring (Faktiske)

1. mai 2011

Datoer for studieregistrering

Først innsendt

16. mai 2008

Først innsendt som oppfylte QC-kriteriene

19. mai 2008

Først lagt ut (Anslag)

20. mai 2008

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

19. mai 2014

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. mai 2014

Sist bekreftet

1. desember 2013

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 1160.46
  • 2007-002631-86 (EudraCT-nummer: EudraCT)

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Dabigatran etexilate

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Poland

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

3
Abonnere